(Q42595256)

English

Phase I, dose-finding study of AZD8931, an inhibitor of EGFR (erbB1), HER2 (erbB2) and HER3 (erbB3) signaling, in patients with advanced solid tumors.

scientific article published on 16 April 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23589215%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Phase I, dose-finding study of AZD8931, an inhibitor of EGFR (erbB1), HER2 (erbB2) and HER3 (erbB3) signaling, in patients with advanced solid tumors (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23589215%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Vladimir Moiseyenko

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23589215%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

author name string

S Tjulandin

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23589215%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

V Semiglazov

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23589215%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

G Manikhas

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23589215%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

M Learoyd

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23589215%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

A Saunders

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23589215%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

M Stuart

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23589215%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

U Keilholz

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23589215%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

publication date

16 April 2013

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23589215%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Investigational New Drugs

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23589215%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

32

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23589215%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23589215%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

145-153

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23589215%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9963-6

21 January 2018

EGF-ERBB signalling: towards the systems level

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9963-6

21 January 2018

The juxtamembrane region of EGFR takes center stage.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9963-6

21 January 2018

The ErbB receptor tyrosine family as signal integrators

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9963-6

21 January 2018

ERBB receptors and cancer: the complexity of targeted inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9963-6

21 January 2018

Epidermal growth factor receptor: mechanisms of activation and signalling.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9963-6

21 January 2018

Novel anticancer targets: revisiting ERBB2 and discovering ERBB3.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9963-6

21 January 2018

EGFR antagonists in cancer treatment

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9963-6

21 January 2018

EGFR and cancer prognosis

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9963-6

21 January 2018

AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9963-6

21 January 2018

Mechanisms of resistance to EGFR TKIs and development of a new generation of drugs in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9963-6

21 January 2018

Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9963-6

21 January 2018

Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9963-6

21 January 2018

ErbB-3 predicts survival in ovarian cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9963-6

21 January 2018

The role of the ErbB family members in non-small cell lung cancers sensitive to epidermal growth factor receptor kinase inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9963-6

21 January 2018

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9963-6

21 January 2018

A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9963-6

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9963-6

21 January 2018

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9963-6

21 January 2018

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9963-6

21 January 2018

Overview of the tolerability of gefitinib (IRESSA) monotherapy : clinical experience in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9963-6

21 January 2018

Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome?

1 reference

https://pubmed.ncbi.nlm.nih.gov/23589215

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/23589215

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers

1 reference

https://pubmed.ncbi.nlm.nih.gov/23589215

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparative study on overexpression of HER2/neu and HER3 in gastric cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23589215

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High c-erbB-3 protein expression is associated with shorter survival in advanced non-small cell lung carcinomas.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23589215

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression of erbB-3 protein in colorectal adenocarcinoma: correlation with poor survival

1 reference

https://pubmed.ncbi.nlm.nih.gov/23589215

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers

1 reference

https://pubmed.ncbi.nlm.nih.gov/23589215

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10637-013-9963-6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23589215%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Dimensions Publication ID

0 references

release_qczjh4prbff3ziseldlim2f7l4

1 reference

https://api.fatcat.wiki/v0/release/qczjh4prbff3ziseldlim2f7l4

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23589215%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42595256&oldid=2205519781"